MedTrace Logo

Pack Cross Linking for Infectious Keratitis

NCT05881187 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-05-31

No results posted yet for this study

Summary

The primary aim of this study is to investigate the efficiency of PACK\_ CXL in treatment of infectious keratitis and analyze postoperative outcomes.

Conditions

  • Infectoius Keratitis

Interventions

DRUG

Riboflavin

topical application of riboflavin followed by cross linking

DRUG

Antibotice.g vigamox ED Antifungal e.g Dflucan

topical application of antimicropial therapy

DEVICE

pack cross linking

TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2024-04-30
Completion
2024-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05881187 on ClinicalTrials.gov